Divided panel calls for restrictions on diabetes drug Avandia

The Food and Drug Administration advisory panel that has spent the past two days looking into claims that Avandia causes heart attacks voted Wednesday to allow the drug to remain on the market. Shares of the diabetes drug’s manufacturer, GlaxoSmithKline, rose 1.8 percent.

Twelve people on the 33-member panel voted to pull the drug from the market, and three voted for no change. The others called for extra safety warnings and restrictions on its use.

The FDA will seal the drug’s fate at a later date. The agency has come under fire for being too cozy with drug makers, and some people — including Rep. Rosa DeLauro (D-Conn.) and the consumer advocacy group Public Citizen — have already called for Avandia to be pulled from the market.